RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.

doi:10.1158/0008-5472.CAN-25-0600

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.

Cancer research - 16 Jan 2026

Solanki Hitendra S, Shah Harshit, Imbody Denis, Desai Bina, Kato Ryoji, Miroshnychenko Daria, Stern Yaakov E, Majumder Anurima, Sarcar Bhaswati, Xieraili Aobuli, Stewart Paul A, Fang Bin, Zhang Yonghong, Yao Jiqiang, Darville Lancia N, Koomen John M, Rix Uwe, Evans James W, Yang Yu Chi, Ahler Ethan, Marusyk Andriy, Singh Mallika, Aronchik Ida, Haura Eric B

Abstract excerpt

Small-molecule KRASG12C(OFF) inhibitors that bind to the inactive GDP-bound state of KRAS have demonstrated efficacy in patients with KRASG12C-mutant tumors, yet responses tend to be transient because of emergence of on-treatment resistance. Recently, RAS(ON) G12C-selective inhibitors, which bind to the active GTP-bound state of RAS, were described, and elironrasib is undergoing evaluation in multiple clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to Guanosine Triphosphate

Share to Lung Neoplasms

Share to Mice

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41165456
DOI: 10.1158/0008-5472.CAN-25-0600
PMCID: PMC12962340

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.PMID 41165456Read ↗

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.Semantic proximity Read ↗

Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancerSemantic proximity Read ↗

From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.Semantic proximity Read ↗

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.Semantic proximity Read ↗

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.Semantic proximity Read ↗

KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.Semantic proximity Read ↗

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.Semantic proximity Read ↗

Acquired Resistance to KRASG12C Inhibition in Cancer.Semantic proximity Read ↗

Diverse alterations associated with resistance to KRAS(G12C) inhibition.Semantic proximity Read ↗

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapySemantic proximity Read ↗

Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.Semantic proximity Read ↗

Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.